168 related articles for article (PubMed ID: 7744836)
1. Development of a novel recombinant serpin with potential antithrombotic properties.
Hopkins PC; Crowther DC; Carrell RW; Stone SR
J Biol Chem; 1995 May; 270(20):11866-71. PubMed ID: 7744836
[TBL] [Abstract][Full Text] [Related]
2. Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition.
Filion ML; Bhakta V; Nguyen LH; Liaw PS; Sheffield WP
Biochemistry; 2004 Nov; 43(46):14864-72. PubMed ID: 15544357
[TBL] [Abstract][Full Text] [Related]
3. Evolution of serpin specificity: cooperative interactions in the reactive-site loop sequence of antithrombin specifically restrict the inhibition of activated protein C.
Hopkins PC; Pike RN; Stone SR
J Mol Evol; 2000 Nov; 51(5):507-15. PubMed ID: 11080374
[TBL] [Abstract][Full Text] [Related]
4. Role of the P2 residue in determining the specificity of serpins.
Djie MZ; Le Bonniec BF; Hopkins PC; Hipler K; Stone SR
Biochemistry; 1996 Sep; 35(35):11461-9. PubMed ID: 8784202
[TBL] [Abstract][Full Text] [Related]
5. Role of Leu99 of thrombin in determining the P2 specificity of serpins.
Rezaie AR
Biochemistry; 1997 Jun; 36(24):7437-46. PubMed ID: 9200692
[TBL] [Abstract][Full Text] [Related]
6. Thrombin Glu-39 restricts the P'3 specificity to nonacidic residues.
Le Bonniec BF; MacGillivray RT; Esmon CT
J Biol Chem; 1991 Jul; 266(21):13796-803. PubMed ID: 1856211
[TBL] [Abstract][Full Text] [Related]
7. Interaction of activated protein C with serpins.
Hermans JM; Stone SR
Biochem J; 1993 Oct; 295 ( Pt 1)(Pt 1):239-45. PubMed ID: 8216224
[TBL] [Abstract][Full Text] [Related]
8. Fusion of the C-terminal triskaidecapeptide of hirudin variant 3 to alpha1-proteinase inhibitor M358R increases the serpin-mediated rate of thrombin inhibition.
Roddick LA; Bhakta V; Sheffield WP
BMC Biochem; 2013 Nov; 14():31. PubMed ID: 24215622
[TBL] [Abstract][Full Text] [Related]
9. Mutagenesis of recombinant protein C inhibitor reactive site residues alters target proteinase specificity.
Phillips JE; Cooper ST; Potter EE; Church FC
J Biol Chem; 1994 Jun; 269(24):16696-700. PubMed ID: 8206990
[TBL] [Abstract][Full Text] [Related]
10. Importance of the P2 glycine of antithrombin in target proteinase specificity, heparin activation, and the efficiency of proteinase trapping as revealed by a P2 Gly --> Pro mutation.
Chuang YJ; Gettins PG; Olson ST
J Biol Chem; 1999 Oct; 274(40):28142-9. PubMed ID: 10497166
[TBL] [Abstract][Full Text] [Related]
11. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition.
Derechin VM; Blinder MA; Tollefsen DM
J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609
[TBL] [Abstract][Full Text] [Related]
12. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
Sutherland JS; Bhakta V; Sheffield WP
Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
[TBL] [Abstract][Full Text] [Related]
13. Reactive site mutants of recombinant protein C inhibitor.
Cooper ST; Church FC
Biochim Biophys Acta; 1995 Jan; 1246(1):29-33. PubMed ID: 7811727
[TBL] [Abstract][Full Text] [Related]
14. Identification of thrombin residues that modulate its interactions with antithrombin III and alpha 1-antitrypsin.
Le Bonniec BF; Guinto ER; Stone SR
Biochemistry; 1995 Sep; 34(38):12241-8. PubMed ID: 7547966
[TBL] [Abstract][Full Text] [Related]
15. Tracking structural features leading to resistance of activated protein C to alpha 1-antitrypsin.
Shen L; Dahlbäck B; Villoutreix BO
Biochemistry; 2000 Mar; 39(11):2853-60. PubMed ID: 10715104
[TBL] [Abstract][Full Text] [Related]
16. Modeling of serpin-protease complexes: antithrombin-thrombin, alpha 1-antitrypsin (358Met-->Arg)-thrombin, alpha 1-antitrypsin (358Met-->Arg)-trypsin, and antitrypsin-elastase.
Whisstock J; Lesk AM; Carrell R
Proteins; 1996 Nov; 26(3):288-303. PubMed ID: 8953650
[TBL] [Abstract][Full Text] [Related]
17. The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation.
Chuang YJ; Swanson R; Raja SM; Bock SC; Olson ST
Biochemistry; 2001 Jun; 40(22):6670-9. PubMed ID: 11380262
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory properties of the P1 Tyr variant of antithrombin.
Yang L; Manithody C; Qureshi SH; Rezaie AR
Biochemistry; 2010 Mar; 49(12):2680-6. PubMed ID: 20184328
[TBL] [Abstract][Full Text] [Related]
19. Protection by recombinant alpha 1-antitrypsin Ala357 Arg358 against arterial hypotension induced by factor XII fragment.
Schapira M; Ramus MA; Waeber B; Brunner HR; Jallat S; Carvallo D; Roitsch C; Courtney M
J Clin Invest; 1987 Aug; 80(2):582-5. PubMed ID: 3497179
[TBL] [Abstract][Full Text] [Related]
20. Phage display of the serpin alpha-1 proteinase inhibitor randomized at consecutive residues in the reactive centre loop and biopanned with or without thrombin.
Scott BM; Matochko WL; Gierczak RF; Bhakta V; Derda R; Sheffield WP
PLoS One; 2014; 9(1):e84491. PubMed ID: 24427287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
